VWA
UTHR icon

Valued Wealth Advisors’s United Therapeutics UTHR Stock Holding History

Valued Wealth Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4K Buy
21
+4
+24% +$2.25K ﹤0.01% 290
2026
Q1 		$10.1K Buy
+17
New +$8.47K ﹤0.01% 290

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Valued Wealth Advisors's UTHR Position: Q2 2026 in Review

Valued Wealth Advisors increased its United Therapeutics (UTHR) stake by 24% in Q2 2026, buying an estimated $2.25K and bringing the position to 21 shares worth $11.4K. The position accounts for ﹤0.01% of the portfolio, ranked #290.

Valued Wealth Advisors first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Valued Wealth Advisors held 21 shares of United Therapeutics worth $11.4K as of Q2 2026.
  • Valued Wealth Advisors bought 4 United Therapeutics shares in Q2 2026, an estimated $2.25K.
  • United Therapeutics made up ﹤0.01% of Valued Wealth Advisors's portfolio in Q2 2026, its #290 holding.
  • Valued Wealth Advisors first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Valued Wealth Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.